Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:32:37 EDT Sun 05 Oct 2025
Enter Symbol
or Name
USA
CA



Q:MNOV - MEDICINOVA INC - https://www.medicinova.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MNOV - Q5.01.22·1.380.11.28+0.043.229.9311461.24  1.28  1.242.55  1.1319:38:56Sep 2215 min RT 2¢

Recent Trades - Last 10 of 146
Time ETExPriceChangeVolume
19:38:56Q1.280.048
16:10:04Q1.280.041
16:10:04Q1.280.041
16:04:02Q1.280.041
16:00:01Q1.280.048
16:00:01Q1.280.041
16:00:01Q1.280.04175
15:59:50Q1.280.044
15:59:16Q1.280.0478
15:59:16Q1.280.0413

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-09-22 08:00U:MNOVNews ReleaseMediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
2025-09-16 08:00U:MNOVNews ReleaseMediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
2025-09-08 09:00U:MNOVNews ReleaseMediciNova Provides Shareholder Update on Key Developments
2025-09-03 07:00U:MNOVNews ReleaseMediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
2025-08-26 19:00U:MNOVNews ReleaseMediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
2025-07-31 19:30U:MNOVNews ReleaseMediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
2025-07-24 06:00U:MNOVNews ReleaseMediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
2025-04-14 19:00U:MNOVNews ReleaseMediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025
2025-04-08 19:00U:MNOVNews ReleaseFirst Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
2024-12-05 18:00U:MNOVNews ReleaseMediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
2024-11-19 09:00U:MNOVNews ReleaseMediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
2024-11-14 18:00U:MNOVNews ReleaseMediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
2024-11-11 18:00U:MNOVNews ReleaseMediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
2024-10-23 19:00U:MNOVNews ReleaseMediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)